Cargando…
M2e-based universal influenza vaccines: a historical overview and new approaches to development
The influenza A virus was isolated for the first time in 1931, and the first attempts to develop a vaccine against the virus began soon afterwards. In addition to causing seasonal epidemics, influenza viruses can cause pandemics at random intervals, which are very hard to predict. Vaccination is the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800501/ https://www.ncbi.nlm.nih.gov/pubmed/31629405 http://dx.doi.org/10.1186/s12929-019-0572-3 |
_version_ | 1783460457457123328 |
---|---|
author | Mezhenskaya, Daria Isakova-Sivak, Irina Rudenko, Larisa |
author_facet | Mezhenskaya, Daria Isakova-Sivak, Irina Rudenko, Larisa |
author_sort | Mezhenskaya, Daria |
collection | PubMed |
description | The influenza A virus was isolated for the first time in 1931, and the first attempts to develop a vaccine against the virus began soon afterwards. In addition to causing seasonal epidemics, influenza viruses can cause pandemics at random intervals, which are very hard to predict. Vaccination is the most effective way of preventing the spread of influenza infection. However, seasonal vaccination is ineffective against pandemic influenza viruses because of antigenic differences, and it takes approximately six months from isolation of a new virus to develop an effective vaccine. One of the possible ways to fight the emergence of pandemics may be by using a new type of vaccine, with a long and broad spectrum of action. The extracellular domain of the M2 protein (M2e) of influenza A virus is a conservative region, and an attractive target for a universal influenza vaccine. This review gives a historical overview of the study of M2 protein, and summarizes the latest developments in the preparation of M2e-based universal influenza vaccines. |
format | Online Article Text |
id | pubmed-6800501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68005012019-10-22 M2e-based universal influenza vaccines: a historical overview and new approaches to development Mezhenskaya, Daria Isakova-Sivak, Irina Rudenko, Larisa J Biomed Sci Review The influenza A virus was isolated for the first time in 1931, and the first attempts to develop a vaccine against the virus began soon afterwards. In addition to causing seasonal epidemics, influenza viruses can cause pandemics at random intervals, which are very hard to predict. Vaccination is the most effective way of preventing the spread of influenza infection. However, seasonal vaccination is ineffective against pandemic influenza viruses because of antigenic differences, and it takes approximately six months from isolation of a new virus to develop an effective vaccine. One of the possible ways to fight the emergence of pandemics may be by using a new type of vaccine, with a long and broad spectrum of action. The extracellular domain of the M2 protein (M2e) of influenza A virus is a conservative region, and an attractive target for a universal influenza vaccine. This review gives a historical overview of the study of M2 protein, and summarizes the latest developments in the preparation of M2e-based universal influenza vaccines. BioMed Central 2019-10-19 /pmc/articles/PMC6800501/ /pubmed/31629405 http://dx.doi.org/10.1186/s12929-019-0572-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Mezhenskaya, Daria Isakova-Sivak, Irina Rudenko, Larisa M2e-based universal influenza vaccines: a historical overview and new approaches to development |
title | M2e-based universal influenza vaccines: a historical overview and new approaches to development |
title_full | M2e-based universal influenza vaccines: a historical overview and new approaches to development |
title_fullStr | M2e-based universal influenza vaccines: a historical overview and new approaches to development |
title_full_unstemmed | M2e-based universal influenza vaccines: a historical overview and new approaches to development |
title_short | M2e-based universal influenza vaccines: a historical overview and new approaches to development |
title_sort | m2e-based universal influenza vaccines: a historical overview and new approaches to development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800501/ https://www.ncbi.nlm.nih.gov/pubmed/31629405 http://dx.doi.org/10.1186/s12929-019-0572-3 |
work_keys_str_mv | AT mezhenskayadaria m2ebaseduniversalinfluenzavaccinesahistoricaloverviewandnewapproachestodevelopment AT isakovasivakirina m2ebaseduniversalinfluenzavaccinesahistoricaloverviewandnewapproachestodevelopment AT rudenkolarisa m2ebaseduniversalinfluenzavaccinesahistoricaloverviewandnewapproachestodevelopment |